ClinicalTrials.gg

Program

TQB3911

A development code. Also written as “TQB3911 tablets”.

In Sino Biopharmaceutical's pipeline, BCR-ABL1酪氨酸激酶抑制剂. Its studies are mostly in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, led by Sino Biopharmaceutical.

Furthest: phase 1, since Oct 27, 20241 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical11 open or runningphase 1since Oct 27, 2024Oct 27, 2024none ahead
  • Named in Sino Biopharmaceutical’s own pipeline as TQB3911, phase 1, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 27, 2024First study: phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveFirst studyNCT06672263 · 120 planned · China

TargetBeta

“BCR-ABL1酪氨酸激酶抑制剂”the company's pipeline, read by Claude · source

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
imatinibruleNovartisphase 470
nilotinibruleNovartisphase 457
asciminibruleNovartisphase 416
olverembatinibruleAscentage Pharma Group Internationalphase 310
EmbibatinibHansoh Pharmaceutical Groupphase 37

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06672263Leukemia, Myelogenous, Chronic, BCR-ABL Positive · China1Not yet recruitingSep 2026120

How it is read

Names in the registry

  • “TQB3911 tablets”, 1 entry

Codes read as this program: TQB3911.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.